GSK PLC 2015 AR2
The report highlights GlaxoSmithKline's progress in 2015, including the completion of a major three-part transaction with Novartis to strengthen its Vaccines and Consumer Healthcare businesses. The company accelerated new product sales to 52.0 billion and achieved 51.0 billion in incremental annual cost savings from integration and restructuring. In R&D, GSK received regulatory approvals for its severe asthma treatment Nucala and a positive scientific opinion for its malaria vaccine Mosquirix. Additionally, the company reduced its operational carbon emissions by 2% and met its 2015 water reduction target a year early.
Company: GSK PLC
Sector: Manufacturing
Country: United Kingdom
Year: 2015
Type: AR2
Pages: 264
Back to company
GSK PLC
Annual Report
The report highlights GlaxoSmithKline's progress in 2015, including the completion of a major three-part transaction with Novartis to strengthen its Vaccines and Consumer Healthcare businesses. The company accelerated new product sales to 52.0 billion and achieved 51.0 billion in incremental annual cost savings from integration and restructuring. In R&D, GSK received regulatory approvals for its severe asthma treatment Nucala and a positive scientific opinion for its malaria vaccine Mosquirix. Additionally, the company reduced its operational carbon emissions by 2% and met its 2015 water reduction target a year early.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2015
Reporting Period
Jan 1, 2015 - Dec 31, 2015
Fiscal Year
2015
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Renewable Energy
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees